NIAID Accomplishments

NIAID conducts and supports research to better understand, treat, and ultimately prevent infectious and immune-mediated diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and abroad. This page highlights notable scientific advances made by NIAID laboratories and NIAID-funded researchers.

NIAID Research Journeys

Explore the stories behind how NIAID-funded basic and clinical research paved the way for the development of important therapeutics and vaccines.

Systems Biology Program for Infectious Diseases History

In 2008, NIAID established the Systems Biology Program for Infectious Disease Research. In 2012/2013, NIAID continued the Systems Biology Program to further develop an interdisciplinary community that integrates experimental biology, computational tools and modeling across temporal and spatial scales towards a better understanding of infectious diseases. These efforts laid the groundwork in 2016 to support Systems Biology centers that address antibacterial resistance and centers funded in 2018 to advance models across diverse pathogens. 

Transplant Infectious Diseases Fellowship

Transplant Infectious Diseases Program Attendings. From left to right: Mary Czech, Jennifer Cuellar-rodriguez, Juan Gea-Banacloche

Transplant Infectious Diseases Program Attendings. From left to right: Mary Czech, Jennifer Cuellar-rodriguez, Juan Gea-Banacloche

Credit: NIAID

The NIH National Institute of Allergy Infectious Diseases (NIAID) is offering a funded 13-month clinical fellowship in Transplant Infectious Diseases (TID). The fellowship is fully funded and includes collaboration with experts across major transplant institutions. The program includes TID training in hematopoietic stem cell transplants for malignant and nonmalignant conditions as well as solid organ.

Collaborating with Experts Across Major Transplant Institutes

TID Training

This post ACGME ID Fellowship year-long training will prepare candidates for the rigors of both HSCT and solid organ transplant ID. 

The Fellow will rotate on both the inpatient and out consultative Transplant services at the NIH and outpatient consultative Transplant services at the NIH and John's Hopkins. 

  • Hematopoietic Stem cell transplants (HSCT):

    • The NIH performs HSCT in both malignant and nonmalignant conditions
      • Primary Immunodeficiency
      • Sickle Cell Anemia
      • Severe Aplastic Anemia
      • Expanded Cord blood transplant
      • Haplo-identical
    • CAR-T therapy
    • Solid organ Transplantation including:
      • HLA/ABO-incompatible kidney transplantation
      • HIV+ renal transplantation
    • Composite tissue allotransplantation

    The fellow will spend 4-5 months at NIH and JHH during this intensive clinical year.

Focus

  • The interaction between immune function, infection assessment pre- and post-transplantation.
  • Management and prevention of infection pre-transplant.
  • Primary and secondary prevention of bacterial, viral, and fungal infections throughout transplant.
  • Multidisciplinary approach to transplant in patients and families with immune deficiency.
  • Understanding the molecular techniques utilized to diagnose infection in the setting of transplantation.
  • Research protocols that utilize immune modulation in the setting of transplant and subsequent development of infection.

Qualifications

  • Current or graduate fellow in good standing in an ACGME-accredited Infectious Disease Fellowship Program
  • Board eligible or board certified in Infectious Diseases
  • Board certified in Internal Medicine or Medicine and Pediatric board certified

This fellowship follows the academic year with a start date of July 1. Please forward a curriculum vitae and statement of interest and three letters of recommendation (including Program Director).

Compensations

Vacation

During the year, fellows earn six hours of annual leave every two week and three hours of sick leave. For more information read the full NIH vacation policy.

Transportation

Free parking is available at all clinical sites. NIH, at outside. NIH will reimburse the excess miles of those usually traveled while rotating at outside hospitals.

Conference

Each fellow is funded to go to one national meeting.

Benefits

  • Benefits Funding is provided to attend one national transplant ID meeting. 
  • Administrative time and funding is provided to attend the GW ID Board Review Course held yearly.
  •  Reimbursement for the cost of the local license.

How to Apply

Applicants should be current or graduate fellows in good standing in an ACGME-accredited Infectious Disease Fellowship Program. All applicants must be board eligible or board certified in Infectious Diseases as well as board certified in Internal Medicine or Medicine and Pediatric board certified. This fellowship follows the academic year with a start date of July 1. Please forward a curriculum vitae and statement of interest and two letters of recommendation to:

Contact Information

You may also contact the NIAID TID Fellowship Program office with questions.

Christa S. Zerbe, M.D.
Director, Transplant Infectious Diseases Fellowship Program

Julie Hoehl
Fellowship Program Coordinator

Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge

This is a protocol to screen healthy volunteers for future and ongoing LMIV malaria drug, vaccine, or controlled human malaria infection (CHMI) trials. A complete medical history and blood and urine samples will be obtained for evaluation.  

Contact Information

Contact the LMIV Clinical Team  

Email: LMIVClinicalTrial@mail.nih.gov 

Phone: 240-627-3355 

Sinu P. John, Ph.D.

Section or Unit Name
Signaling Systems Section
Exclude from directory
Off
Section/Unit: Year Established
Section/Unit: Location
This Researcher/Clinician’s Person Page
Program Description

Our research focuses primarily on identification of cell intrinsic factors (protein coding and non-coding genes) associated with regulation of macrophage signaling. We use high throughput genome-wide techniques such as RNAi screening, CRISPR screening, RNA-seq, ATAC-seq, etc. to identify and characterize the genes and gene-regulatory mechanisms that modulate the immune response in macrophage cells. In addition, we study the role of various external factors (environmental pollutants, drugs, diet, etc.) that modulate the immune response in macrophages with an emphasis to develop therapeutic candidates for the treatment of infectious and immune diseases. We use both bacterial and several emerging viral models such as HIV, Influenza, SARS-CoV-2, etc. to study the impact of immune regulation by various intrinsic and external factors.

Selected Publications

John SP, Singh A, Sun J, Pierre MJ, Alsalih L, Lipsey C, Traore Z, Balcom-Luker S, Bradfield CJ, Song J, Markowitz TE, Smelkinson M, Ferrer M, Fraser IDC. Small-molecule screening identifies Syk kinase inhibition and rutaecarpine as modulators of macrophage training and SARS-CoV-2 infection. Cell Rep. 2022 Oct 4;41(1):111441.

John SP, Sun J, Carlson RJ, Cao B, Bradfield CJ, Song J, Smelkinson M, Fraser IDC. IFIT1 Exerts Opposing Regulatory Effects on the Inflammatory and Interferon Gene Programs in LPS-Activated Human Macrophages. Cell Rep. 2018 Oct 2;25(1):95-106.e6.

John SP, Chin CR, Perreira JM, Feeley EM, Aker AM, Savidis G, Smith SE, Elia AE, Everitt AR, Vora M, Pertel T, Elledge SJ, Kellam P, Brass AL. The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol. 2013 Jul;87(14):7837-52.

Zhu J, Gaiha GD, John SP, Pertel T, Chin CR, Gao G, Qu H, Walker BD, Elledge SJ, Brass AL. Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep. 2012 Oct 25;2(4):807-16.

Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ, Wise HM, Kane L, Goulding D, Digard P, Anttila V, Baillie JK, Walsh TS, Hume DA, Palotie A, Xue Y, Colonna V, Tyler-Smith C, Dunning J, Gordon SB; GenISIS Investigators; MOSAIC Investigators; Smyth RL, Openshaw PJ, Dougan G, Brass AL, Kellam P. IFITM3 restricts the morbidity and mortality associated with influenza. Nature. 2012 Mar 25;484(7395):519-23.

Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig E, Adams DJ, Xavier RJ, Farzan M, Elledge SJ. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell. 2009 Dec 24;139(7):1243-54.

Visit PubMed for a complete publication listing.

Major Areas of Research
  • Genes and epigenetic states modulating macrophage signaling and function
  • Identification and characterization of trained immunity stimuli
  • Applications of trained immunity in infectious and immune disease

Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)

The purpose of this reissued Notice of Funding Opportunity (NOFO) is to support high-risk, high-impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high-risk, high-impact nature of this research, this NOFO supports a Go/No-Go approach to funding high risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated Go/No-Go criteria by the end of Year 2.

STrengthening Research Opportunities for NIH Grants (STRONG)—Structured Institutional Needs Assessment and Action Plan Development for Resource Limited Institutions (RLIs) (UC2 - Clinical Trial Not Allowed)

Brain-Penetrating Drug Candidate Effective Against Deadly Encephalitis Viruses

Media Type
Article
Publish or Event Date
Research Institution
University of Wisconsin–Madison’s School of Pharmacy
Short Title
Brain-Penetrating Drug Candidate Effective Against Deadly Encephalitis Viruses
Content Coordinator
Content Manager

Researchers Warn of Tick-Borne Disease Babesiosis

Tick-borne Powassan virus is being transmitted in concentrated clusters in New England, Yale study says

Media Type
Article
Publish or Event Date
Research Institution
Yale University
Short Title
Tick-borne Powassan virus is being transmitted in concentrated clusters in New England, Yale study says
Content Coordinator
Content Manager